Израел - Хебрејски - Ministry of Health

neopharm ltd, israel - recombinant human parathyroid hormone - recombinant human parathyroid hormone 50 mcg - parathyroid hormone

Израел - Хебрејски - Ministry of Health

neopharm ltd, israel - recombinant human parathyroid hormone - recombinant human parathyroid hormone 75 mcg - parathyroid hormone

Израел - Хебрејски - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Израел - Хебрејски - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Израел - Хебрејски - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Израел - Хебрејски - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Израел - Хебрејски - Ministry of Health

bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 500 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage. kogenate fs is not indicated for the treatment of von willebrand’s disease.

Израел - Хебрејски - Ministry of Health

bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 1000 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children under with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.

Израел - Хебрејски - Ministry of Health

cure medical & technical supply - ergocalciferol; phytomenadione; retinol palmitate; tocopherol - תרכיז להכנת תמיסה לאינפוזיה - phytomenadione 15 mcg/ml; ergocalciferol 0.5 mcg/ml; tocopherol 0.91 mg/ml; retinol palmitate 194.1 mcg/ml - combinations - combinations - vitalipid n adult is indicated in adult and children above 11 years of age as a supplement in iv nutrition to meet the daily requirement of the fat soluble vitamins a, d2, e,k1.

Израел - Хебрејски - Ministry of Health

cure medical & technical supply - purified fish oil; refined olive oil; soya oil; triglycerides, medium-chain - תחליב לאינפוזיה - triglycerides, medium-chain 60 g/l; soya oil 60 g/l; refined olive oil 50 g/l; purified fish oil 30 g/l - combinations - combinations - supply of energy and essential fatty acids and omega-3 fatty acids to patients who weight not less than 1 kg, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.